NEWSROOM

MedTech

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

POMPANO BEACH, Fla., April 1, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces it has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC The company is currently undergoing a mandatory Securities Exchange Commission (SEC) review process related to its Form 10 registration...

read more
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of...

read more
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

The presentation will be webcast at 1:30 PM ET on April 10, 2025 POMPANO BEACH, Fla., March 27, 2025 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting...

read more
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

POMPANO BEACH, Fla., January 13, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: Fourth quarter net revenue is expected to...

read more
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 - PRISM MediaWire - BioStem Technologies, Inc.  (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850